Exodus Point Capital Management, LP Humanigen, Inc Transaction History

Exodus Point Capital Management, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	SELL	$0.15 - $3.02 $4,825 - $97,156	-32,171 Closed	0 $0
Q2 2022 Aug 19, 2022	SELL	$1.76 - $3.33 $3,497 - $6,616	-1,987 Reduced 5.82%	32,171 $57,000
Q1 2022 May 13, 2022	SELL	$1.81 - $3.97 $232,985 - $511,022	-128,721 Reduced 79.03%	34,158 $103,000
Q4 2021 Feb 11, 2022	BUY	$3.66 - $8.22 $596,137 - $1.34 Million	162,879 New	162,879 $606,000
Q2 2021 Aug 16, 2021	SELL	$13.54 - $22.74 $405,712 - $681,381	-29,964 Closed	0 $0

Q1 2021 May 17, 2021	SELL	$12.91 - $23.83 $1.23 Million - $2.28 Million	-95,649 Reduced 76.15%	29,964 $572,000
Q4 2020 Feb 16, 2021	BUY	$7.97 - $21.66 $742,724 - $2.02 Million	93,190 Added 287.42%	125,613 $2.2 Million
Q3 2020 Nov 16, 2020	BUY	$8.0 - $28.5 $259,384 - $924,055	32,423 New	32,423 $345,000

558K

Ticker HGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,661,000
Description
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.